FibroGen, a biotech backed by Astellas and AstraZenec developing therapies for anemia and fibrosis, raised $146 million by offering 8.1 million shares at $18, toward the top of the $16 to $19 range. FibroGen plans to list on the NASDAQ under the symbol...read more
Akebia Therapeutics, a biotech developing a breakthrough anemia treatment with a once-daily oral dose, raised $100 million in an upsized IPO by offering 5.9 million shares at $17, the high end of the range of $14 to $17. The company had originally planned to...read more
Last week Coupons.com (COUP), the year's third tech IPO (after Varonis (VRNS) and Care.com (CRCM)), continued a strong run for the sector with an 88% first-day gain; the three offerings now average an 83% total return to date. Others hope to cash in on...read more
Feeling anemic? Biotech FibroGen prices IPO at $18, toward the top of the range
FibroGen, a biotech backed by Astellas and AstraZenec developing therapies for anemia and fibrosis, raised $146 million by offering 8.1 million shares at $18, toward the top of the $16 to $19 range. FibroGen plans to list on the NASDAQ under the symbol...read more
Akebia Therapeutics prices upsized IPO at $17, the high end of the range
Akebia Therapeutics, a biotech developing a breakthrough anemia treatment with a once-daily oral dose, raised $100 million in an upsized IPO by offering 5.9 million shares at $17, the high end of the range of $14 to $17. The company had originally planned to...read more
9 US IPOs planned for the week of Mar 17
The following IPOs are expected to price this week: A10 Networks (ATEN), which provides software-based appliances that optimize data center performance, plans to raise...read more
US IPO Recap: Coupons.com jumps 88% and Biomet files for an IPO
Last week Coupons.com (COUP), the year's third tech IPO (after Varonis (VRNS) and Care.com (CRCM)), continued a strong run for the sector with an 88% first-day gain; the three offerings now average an 83% total return to date. Others hope to cash in on...read more